• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors

    11/19/24 8:00:00 AM ET
    $GNLX
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNLX alert in real time by email

    Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the addition of industry veterans John Smither and Jim Williams, MBA, as Senior Advisors.

    "John and Jim are seasoned veterans in the field, and each brings a differentiated skill set that will enable us to strengthen our execution across the private and public investment strategies of the firm," said Patrick Heron, Managing Partner at FLS.

    John has over 25 years of financial experience in the biopharmaceutical industry. Before joining FLS, John served as the Chief Financial Officer of Arcutis Biotherapeutics, Inc., where he led the company's successful initial public offering and four follow-on financings. Prior to Arcutis, Smither served as the Chief Financial Officer at Sienna Biopharmaceutics, Kite Pharma, a Gilead Company, Unity Biotechnology and Kythera Biopharmaceuticals. John held several financial positions of increasing responsibility, including Vice President of Finance and Administration for Amgen's European operations in 28 countries, and served as Executive Director of Corporate Accounting. John is currently on the Boards of NewAmsterdam Pharma (NASDAQ:NAMS) and Genlux Corporation (NASDAQ:GNLX).

    "The FLS team has created and supported many successful life sciences companies," said John. "I am eager to join this team and help make a meaningful impact across the FLS portfolio to continue bringing important innovations to patients in need."

    Jim has over 35 years of investment strategy expertise. Prior to joining FLS, he was the first Chief Investment Officer for the J. Paul Getty Trust in Los Angeles which provides funding for Getty's museums, conservation projects, library and grant program, and a staff of over 1,500 employees focused on the visual arts. Before that, Jim was President of Harbor Capital Advisors and Harbor's family of mutual funds. Jim serves on the Boards of Trustees for Ariel mutual funds and SEI mutual funds. He sits on the Board of the Toigo Foundation, which promotes opportunities for minorities in the financial services industry.

    "I appreciate the commitment FLS has made over the years to deliver novel therapeutics with tangible effects on human health worldwide," said Jim. "I look forward to contributing to the team's strategy of accelerating the long-term growth and success of promising biotech companies."

    About Frazier Life Sciences

    Frazier Life Sciences invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences manages over $3.9 billion in capital, including Venture Funds focusing on company creation and private companies and the long-only Public Fund focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by FLS, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Palo Alto, Calif. (headquarters), San Diego, Seattle, Boston, New York and London.

    For more information about Frazier Life Sciences, please visit frazierls.com and follow on LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241119599873/en/

    Get the next $GNLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GNLX
    $NAMS

    CompanyDatePrice TargetRatingAnalyst
    NewAmsterdam Pharma Company N.V.
    $NAMS
    6/17/2025$42.00Buy
    Citigroup
    NewAmsterdam Pharma Company N.V.
    $NAMS
    6/10/2025$44.00Buy
    Stifel
    NewAmsterdam Pharma Company N.V.
    $NAMS
    6/4/2025$42.00Overweight
    Cantor Fitzgerald
    NewAmsterdam Pharma Company N.V.
    $NAMS
    12/30/2024$48.00Buy
    H.C. Wainwright
    Genelux Corporation
    $GNLX
    10/29/2024$8.00Buy
    Guggenheim
    Genelux Corporation
    $GNLX
    8/28/2024$10.00Buy
    ROTH MKM
    NewAmsterdam Pharma Company N.V.
    $NAMS
    5/15/2024Buy
    TD Cowen
    NewAmsterdam Pharma Company N.V.
    $NAMS
    3/14/2024$35.00Sector Outperform
    Scotiabank
    More analyst ratings

    $GNLX
    $NAMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Topper James N bought $167,381 worth of Ordinary Shares (8,584 units at $19.50) (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      6/18/25 4:42:40 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Topper James N bought $25,521 worth of Ordinary Shares (1,135 units at $22.49) (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      3/28/25 5:36:48 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Topper James N bought $84,203 worth of Ordinary Shares (4,005 units at $21.02) (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      3/6/25 5:32:07 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    $NAMS
    SEC Filings

    See more
    • NewAmsterdam Pharma Company N.V. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)

      6/11/25 9:00:41 AM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NewAmsterdam Pharma Company N.V. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)

      6/9/25 7:28:48 AM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by NewAmsterdam Pharma Company N.V.

      8-K - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)

      6/6/25 4:35:38 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    $NAMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

      WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2025 and provided general business updates.   "The first quarter of 2025 has been highly productive and sets a strong foundation for the year ahead. We are well positioned to advance Olvi-Vec across multiple high-need cancer indications, with encouraging regulatory feedback from the FDA on our OnPrime Phase 3 registrational trial in resistant/refractory ovarian cancer, promising early lung cancer clinical data from our ongoing Phase 1b/2 study, and increasing patient enrollment in our U.S. Ph

      5/6/25 4:10:00 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference

      WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, CFO, will discuss clinical-stage programs and upcoming milestones in a fireside chat at the Citizens Life Sciences Conference taking place May 7-8, 2025, in New York. The conversation with Biotech Equity Research Managing Director, Silvan Tuerkcan, PhD, is scheduled to begin at 1:30 p.m. ET on Thursday, May 8, 2025. A webcast link for the event will be available at https://wsw.com/webcast/jmp65/gnlx/1693890. An archived replay will be available for a

      5/1/25 4:05:00 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

      NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Adele Gulfo as an independent director to its Board of Directors. Ms. Gulfo is an established pharmaceutical leader with over three decades of experience in the healthcare industry, distinguished by her expertise in global strategy, operations leadership, and the

      4/17/25 4:01:00 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care